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AbstrAct
Objective this analysis explored the association of 
treatment adherence with beliefs about medication, patient 
demographic and disease characteristics and medication 
types in rheumatoid arthritis (ra), psoriatic arthritis (Psa) 
or ankylosing spondylitis (aS) to develop adherence 
prediction models.
Methods the population was a subset from align, a 
multicountry, cross-sectional, self-administered survey 
study in adult patients (n=7328) with six immune-
mediated inflammatory diseases who were routinely 
receiving systemic therapy. instruments included Beliefs 
about Medicines Questionnaire (BMQ) and 4-item Morisky 
Medication adherence Scale (MMaS-4©), which was used 
to define adherence.
Results a total of 3390 rheumatological patients were 
analysed (ra, n=1943; Psa, n=635; aS, n=812). Based 
on the strongest significant associations, the adherence 
prediction models included type of treatment, age, race (ra 
and aS) or disease duration (Psa) and medication beliefs 
(ra and Psa, BMQ-general Harm score; aS, BMQ-Specific 
Concerns score). the models had cross-validated areas 
under the receiver operating characteristic curve of 0.637 
(ra), 0.641 (Psa) and 0.724 (aS). Predicted probabilities 
of full adherence (MMaS-4©=4) ranged from 5% to 
96%. adherence was highest for tumour necrosis factor 
inhibitors versus other treatments, older patients and those 
with low treatment harm beliefs or concerns. adherence 
was higher in white patients with ra and aS and in 
patients with Psa with duration of disease <9 years.
Conclusions For the first time, simple medication 
adherence prediction models for patients with ra, Psa and 
aS are available, which may help identify patients at high 
risk of non-adherence to systemic therapies.
Trial registration number actrn12612000977875.
InTROduCTIOn
In rheumatic diseases, adherence to therapy 
is critical to achieving optimal outcomes1–3 
and lowering non-pharmacy healthcare 
costs.4 5 Adherence varies widely, depending 
on the particular rheumatic disease, the 
definition of adherence and the type of 
treatment. Nonetheless, adherence appears 
to be suboptimal; in a systematic literature 
review, values for the proportion of adherent 
patients ranged from 34% to 93% for rheu-
matoid arthritis (RA), 45% to 76% for psori-
atic arthritis (PsA) and 75% for ankylosing 
spondylitis (AS).6 Adherence for rheu-
matic and other chronic diseases is influ-
enced by many factors, including patients’ 
beliefs about the necessity of treatment and 
concerns about potential adverse effects.7 
Beliefs about and adherence to systemic 
medication depend on patient charac-
teristics (eg, age, race and sex), disease 
characteristics, treatment experience and 
treatment patterns, although previous 
Key messages
What is already known about this subject?
 ► adherence to therapy in patients with rheumatic dis-
eases is important for successful outcomes, highly 
variable, often suboptimal and difficult to predict.
What does this study add?
 ► the align study explored the association of patient 
factors with adherence to medications in a popula-
tion with immune-mediated inflammatory diseases, 
including rheumatoid arthritis (ra), psoriatic arthritis 
(Psa) and ankylosing spondylitis (aS).
 ► in align, medication adherence in ra, Psa and 
aS depended more on treatment beliefs than 
disease-related factors.
 ► results from align showed that adherence was 
predicted by current medication type, treatment 
beliefs, age and race or disease duration.
How might this impact on clinical practice?
 ► Simple models, developed from the align data, are 
available and may help identify patients with ra, Psa 
and aS at high risk of non-adherence to systemic 
therapies.
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analyses have produced inconsistent results.8–16 Despite 
evidence about factors being associated with poor or 
high medication adherence in patients, identification 
of patients at high risk of non-adherence remains diffi-
cult. A probabilistic adherence prediction model could 
help rheumatologists identify patients with RA, PsA and 
AS who are at high risk of non-adherence to systemic 
therapies. Interventions that influence medication 
adherence according to such a model, by addressing 
modifiable factors like patients’ beliefs, could help 
maximise adherence. However, little specific informa-
tion is available about the association between medica-
tion adherence and patients’ beliefs regarding conven-
tional synthetic disease-modifying antirheumatic drugs 
(csDMARDs) and tumour necrosis factor inhibitors 
(TNFis) in RA, PsA and AS as well as non-steroidal 
anti-inflammatory drugs (NSAIDs) in AS.
The ALIGN study determined patients’ specific and 
general beliefs towards medications and adherence to 
selected systemic therapies in six immune-mediated 
inflammatory diseases (IMIDs) and explored the associ-
ation of treatment beliefs and other factors with medi-
cation adherence.16 The objective of this analysis was 
to explore the association of patient characteristics and 
attitudes with adherence to csDMARDs and TNFis in 
the subset of ALIGN patients who had RA, PsA and AS 
as well as adherence to NSAIDs in patients with AS and 
to develop models that predict adherence to systemic 
therapy in each of these three rheumatic IMIDs based on 
the strongest significant associations.
MeTHOds
study design and patients
ALIGN was a cross-sectional patient survey study 
conducted across Europe, Canada, Latin America, the 
Asia-Pacific region and the Middle East between June 
2012 and October 2013.16 Patients provided consent 
according to the Declaration of Helsinki. Consecutive 
patient recruitment was carried out if patients agreed to 
participate and met eligibility criteria.16 A total of 7328 
adult patients with RA, PsA, AS, psoriasis, Crohn’s disease 
or ulcerative colitis were enrolled if they were receiving 
conventional and/or biological therapy as part of 
routine management for their moderate to severe IMIDs, 
including any csDMARD, NSAID (patients with AS only), 
glucocorticoid (GC) and/or TNFi. Prior enrolment in a 
registry was neither required nor an exclusion criterion.
study assessments
Assessment methods have been previously reported in 
detail.16 Investigators recorded patient demographics (eg, 
age, sex and race (white/Caucasian, black, Asian, Hispanic, 
other)), disease characteristics (eg, IMID diagnosis, dura-
tion of disease and symptoms since diagnosis and activity 
(collected as ‘severity’) based on investigator opinion 
(mild, mild to moderate, moderate, moderate to severe 
and severe)) and treatment-related variables (eg, current 
and prior treatment and response based on investigator 
opinion (complete, partial, no and inevaluable)) on a case 
report form. Other assessments (eg, questionnaires) were 
patient-reported. Patients’ illness perceptions were meas-
ured by using the Brief Illness Perception Questionnaire 
(BIPQ) which consisted of eight questions that assessed 
the cognitive and emotional aspects of illness perception 
using a 0 to 10 scale.17 The BIPQ has been used in many 
studies with a wide range of patient groups.18 Validation of 
the BIPQ showed that it has good test–retest reliability, with 
Pearson correlation coefficients ranging from 0.42 to 0.75 
depending on the question and length of time between 
the initial test and the retest.17 The Beliefs about Medi-
cines Questionnaire (BMQ) using a 5-point Likert scale 
(1=strongly disagree; 5=strongly agree; multiplied by a 
factor of 5 for this study) was administered to assess general 
(Overuse and Harm subscales) and specific (Concerns and 
Necessity subscales) beliefs about medicines.19 Treatment 
adherence was based on responses to the 4-item Morisky 
Medication Adherence Scale (MMAS-4©),20 which was 
derived from the Morisky, Green and Levine adherence 
scale.20 21 Four questions were asked: (1) Do you ever forget 
to take your medicine? (2) Do you ever have problems 
remembering to take your medication? (3) When you feel 
better, do you sometimes stop taking your medicine? and 
(4) Sometimes if you feel worse when you take your medi-
cine, do you stop taking it?, with yes=0, no=1 and a total 
score range of 0 to 4. The MMAS-4© has been shown to 
be a useful, reliable and valid measure of treatment adher-
ence, with good sensitivity (0.81) and moderate specificity 
(0.44).20 21
statistical analysis
treatments
Patients were grouped based on the treatments they were 
receiving for RA, PsA and AS at the time of the study visit. The 
following treatment categories were considered relevant 
for all three IMIDs: csDMARD therapy (csDMARDs±GCs), 
TNFi monotherapy (TNFi±GCs) and csDMARD-TNFi 
combination therapy (TNFi+csDMARDs±GCs). csDMARDs 
were defined as sulfasalazine, leflunomide, hydroxychlo-
roquine or methotrexate in patients with RA, PsA and AS 
and cyclosporine in patients with PsA. For AS only, addi-
tional categories were also defined because NSAIDs are a 
cornerstone of treatment in this IMID:22–24 NSAID mono-
therapy (NSAIDs±GCs), NSAID-csDMARD combination 
(NSAIDs+csDMARDs±GCs) and NSAID-TNFi combination 
(NSAIDs+TNFi±GCs). NSAIDs were not included as part 
of the treatment categories for RA and PsA because they 
are supportive therapies in these IMIDs but are not disease 
modifying.
To compare patient-reported high adherence (MMAS-4© 
score=4) to a particular medication among the three IMIDs, 
a multivariable logistic regression model was constructed 
with factors for IMID (RA, PsA or AS) and each possible 
kind of treatment. It was possible to compare adherence 
only to treatments that were evaluated in more than one 
IMID, hence, NSAIDs were not modelled. To account for 
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within-patient correlations, a random-effects model was 
used. The reference IMID was PsA, which bears clinical 
resemblances to RA and AS, and the reference treatment 
was TNFi monotherapy.
attitudinal segmentation
The BMQ-Specific Necessity and Concerns subscale ratings 
were analysed in four attitudinal segments, similar to 
the analysis by Aikens et al.25 On a scale from 5 to 25, 
the attitudinal segments were defined as: accepting, with 
BMQ-Specific Necessity score ≥15 and BMQ-Specific Concerns 
score <15; ambivalent, with both scores ≥15; indifferent, with 
both scores <15 and skeptical, with BMQ-Specific Necessity 
score <15 and BMQ-Specific Concerns score ≥15.
regression analysis of factors associated with medication 
adherence
Potential associations of data from study assessments 
with patient-reported high adherence were assessed by 
multivariable logistic regression models. The full model 
included factors for each study assessment. A further 
exploratory analysis included full models plus the addi-
tion of fixed factors for geographic region. For combi-
nation therapy, separate ratings of adherence were 
performed for each treatment component received by 
the patient. To develop a final model, p value-based back-
ward selection approaches (ie, removal of variables based 
on p>0.05) were applied to eliminate extraneous factors 
from the final adherence prediction regression models; 
this approach automatically selected an adequate 
complexity for the model based on the observed data. 
Although backwards selection based on p values was used, 
factors identifying treatment groups were always kept in 
the models, regardless of statistical significance, as this 
was important for the design of the analysis. Furthermore, 
to account for potential within-patient correlations, the 
final models were then refitted with a random-effects 
logistic model with patient indicator as a random inter-
cept. This final refitting procedure was conservative in its 
treatment of predictors, so that only the most informative 
variables were likely to remain significant.
adherence prediction modelling
Two separate approaches were used to independently 
develop two distinct models to predict medication adher-
ence in patients with RA, PsA and AS. The first approach 
was automated and aimed to construct, for each IMID 
(RA, PsA and AS), a model with up to 10 variables with 
the highest possible predictive power. In this more 
complex approach, candidate models were developed 
from the most important factors (based on ORs for risk 
of non-adherence and practical considerations) for the 
individual IMIDs in the multivariable regression anal-
yses. The three reference models for RA, PsA and AS, 
which had the greatest predictive power, comprised as 
many continuous variables as possible. Beginning with a 
full model, the backward selection algorithm removed, 
based solely on statistical estimates (ie, without subjective 
knowledge), the variable with the largest p value. Then, 
in stepwise fashion, it continued removing variables by 
the same rule, stopping when all remaining variables had 
p values less than the prespecified criterion (here, 0.05). 
Therefore, the complexity (number of variables) in the 
final model was determined automatically by the algo-
rithm, without human intervention. Whenever feasible 
while maintaining adequate predictive accuracy, the 
models were simplified by dividing continuous factors 
into dichotomous variables. The final model for each 
rheumatic disease was the one with the highest predictive 
accuracy, as estimated by 5-fold cross-validated area under 
the receiver operating characteristic curve (AUROC) 
while containing a substantial number of dichotomous 
variables.
The second approach was conducted manually and 
aimed to construct for each IMID (RA, PsA and AS) a 
simplified 4-variable adherence prediction model with 
good predictive power. In this less complex approach, the 
choice of four variables balanced practical clinical utility 
against predictive power; furthermore, four variables can 
be conveniently presented in a risk prediction matrix. 
The final simplified model for each rheumatic disease 
was the one with the highest cross-validated AUROC 
while containing a substantial number of dichotomous 
variables. A visual representation of a typical patient 
medication adherence probability profile for each of the 
three final models (RA, PsA, and AS) from the second, 
simplified approach was generated as a tabular matrix. 
For both the 10-variable and 4-variable models, dichot-
omous variables were obtained from AUROC analysis. 
Analyses were conducted with SAS V.9.2 and V.9.4.
ResulTs
Patients
Demographic and disease characteristics
A total of 3390 patients from ALIGN with rheumatic 
IMIDs were analysed (RA, n=1943; PsA, n=635; AS, 
n=812). As expected, the percentages of female 
(highest in RA; lowest in AS) and white (highest in PsA) 
patients varied significantly across the three rheumatic 
conditions, as did patient age (lowest in AS). Race was 
highly dependent on geographic region. The duration 
of symptoms before diagnosis was shortest in RA and 
longest in AS, but mean disease duration was 9–10 years 
for all three evaluated diseases (table 1). Current but 
not prior disease activity, both of which were defined 
by the investigators, differed significantly among the 
three rheumatic indications; moderate, moderate to 
severe or severe current disease activity was reported 
in 29.3%, 24.4% and 25.5% of patients with RA, PsA 
and AS, respectively. The proportion of patients with >3 
prior treatments varied significantly, with the highest 
percentage in patients with RA. Response to current 
treatments also differed significantly among the three 
rheumatic IMIDs. A complete response (defined by 
investigators) was reported in 47.5%, 52.8% and 57.4% 
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Table 1 Patient demographic and disease characteristics, treatments and beliefs about medications
Characteristic
RA population
(n=1943)
PsA population
(n=635)
AS population
(n=812) P Values
Sociodemographic parameters
  Female, n (%) 1597 (82.2) 294 (46.3) 232 (28.6) <0.0001
  White, n (%)* 1351 (70.0) 571 (90.1) 557 (68.8) <0.0001
   Western Europe and Canada 892 (95.5) 443 (98.9) 399 (94.3)
   Eastern Europe and Middle East 360 (83.5) 96 (96.0) 140 (98.6)
   Latin America 31 (8.4) 7 (14.0) 1 (2.4)
   Asia Pacific 68 (32.2) 25 (67.6) 17 (8.3)
  Age, mean±SD (median), years† 54.8±13.5 (56.0) 50.7±12.4 (51.0) 42.5±12.4 (42.0) <0.001
  Duration of formal education, mean±SD (median), 
years‡
11.5±4.6 (12.0) 12.3±4.1 (12.0) 13.0±3.9 (13.0) <0.001
Duration of symptoms before diagnosis, years§ <0.0001
  <1 1042 (53.9) 257 (40.5) 216 (26.6)
  1–3 530 (27.4) 187 (29.5) 181 (22.3)
  >3 362 (18.7) 190 (30.0) 414 (51.0)
Duration of disease, mean±SD (median), years† 9.2±8.8 (6.3) 9.9±9.5 (7.0) 9.3±8.9 (6.1) 0.248 (RA vs PsA)
0.881 (RA vs AS)
0.379 (PsA vs AS)
Current disease activity, n (%)¶,** 0.0194
  Mild or mild to moderate disease 1371 (70.7) 480 (75.6) 604 (74.5)
  ≥Moderate disease 569 (29.3) 155 (24.4) 207 (25.5)
Prior disease activity, n (%)**,†† 0.277
  Mild or mild to moderate disease 318 (16.5) 91 (14.3) 117 (14.6)
  ≥Moderate disease 1611 (83.5) 544 (85.7) 686 (85.4)
>3 prior treatments, n (%) 389 (20.0) 92 (14.5) 125 (15.4) 0.0007
Prior TNFi therapy, n (%) 598 (30.8) 253 (39.8) 411 (50.6) <0.0001
Response to current treatment, n (%)**,‡‡ <0.001
  Complete response 921 (47.5) 335 (52.8) 463 (57.4)
  Partial response 941 (48.5) 270 (42.6) 310 (38.2)
  No response 57 (2.9) 13 (2.1) 25 (3.1)
Duration of current treatment, mean±SD (median), years 5.3±5.3 (3.6) 4.1±4.5 (2.9) 3.8±4.3 (2.6) <0.001 (RA vs PsA and 
AS)
0.263 (PsA vs AS)
Patients currently taking IMID-related drugs by category, 
n (%)
NA
  csDMARD-TNFi combination 640 (32.9) 200 (31.5) 151 (18.6)
  NSAID-TNFi combination NA NA 123 (15.1)
  TNFi monotherapy 175 (9.0) 216 (34.0) 374 (46.1)
  NSAID-csDMARD combination NA NA 60 (7.4)
  csDMARD monotherapy 1128 (58.1) 219 (34.5) 25 (3.1)
  NSAID monotherapy NA NA 79 (9.7)
Patients currently taking IMID-related drugs, n (%) NA
  TNFi 815 (41.9) 416 (65.5) 648 (79.8)
  Methotrexate 1399 (72.0) 343 (54.0) 116 (14.3)
  NSAID NA NA 310 (38.2)
  GC 658 (33.9) 51 (8.0) 51 (6.3)
  Hydroxychloroquine 348 (17.9) 9 (1.4) 1 (0.1)
  Leflunomide 288 (14.8) 50 (7.9) 6 (0.7)
  Aminosalicylate§§ 149 (7.7) 44 (6.9) 123 (15.1)
Continued
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Characteristic
RA population
(n=1943)
PsA population
(n=635)
AS population
(n=812) P Values
  ≥1 other drug¶¶ 27 (1.4) 12 (1.9) 5 (0.6)
BIPQ item score; 0–10 for each component, mean±SD 
(median)***
  1—Consequences 5.3±2.9 (5.0) 5.3±2.8 (5.0) 5.5±2.8 (5.0) 0.870 (RA vs PsA)
0.275 (RA vs AS)
0.459 (PsA vs AS)
  2—Timeline 8.7±2.3 (10.0) 8.9±2.1 (10.0) 8.5±2.3 (10.0) 0.100 (RA vs PsA)
0.003 (RA vs AS)
<0.001 (PsA vs AS)
  8—Emotional Representation 5.3±3.1 (5.0) 5.4±3.1 (6.0) 5.2±3.0 (5.0) 0.301 (RA vs PsA)
0.608 (RA vs AS)
0.194 (PsA vs AS)
BMQ-Specific score; 5–25 for each component, mean±SD 
(median)
   Necessity 19.8±3.4 (20.0) 19.6±3.5 (20.0) 18.9±3.8 (20.0) 0.112 (RA vs PsA)
<0.001 (RA vs AS)
0.001 (PsA vs AS)
   Concerns 14.7±3.9 (15.0) 14.0±3.9 (14.0) 14.2±3.9 (14.0) <0.001 (RA vs PsA and 
AS)
0.261 (PsA vs AS)
BMQ-General Harm score; 4–20, mean±SD (median)††† 10.0±3.0 (10.0) 9.9±3.0 (10.0) 9.5±2.7 (9.0) 0.301 (RA vs PsA)
<0.001 (RA vs AS)
0.016 (PsA vs AS)
Treatments: csDMARD monotherapy=csDMARDs±GCs; csDMARD-TNFi combination=TNFi +csDMARDs±NSAIDs±GCs; NSAID 
monotherapy=NSAIDs±GCs; NSAID-csDMARD combination=csDMARDs +NSAIDs±GCs; NSAID-TNFi combination=TNFi +NSAIDs±GCs;TNFi 
monotherapy=TNFi±GCs.
P values were from a Wilcoxon (continuous variables) or Pearson chi-square (categorical variables) test.
*Data missing for 16 patients (RA, n=13; PsA, n=1; AS, n=2).
†Data missing for 7 patients (RA, n=6; PsA, n=1).
‡Data missing for 117 patients (RA, n=64; PsA, n=22; AS, n=31).
§Data missing for 11 patients (RA, n=9; PsA, n=1; AS, n=1).
¶Data missing for 4 patients (RA, n=3; AS, n=1).
**Assessed by treating physician; prior and current disease activity was evaluated using a 5-point rating scale (ie, mild, mild to moderate, moderate, 
moderate to severe, severe), and treatment response was categorised as ‘complete response’, ‘partial response’, ‘no response’ or ‘not evaluable’.
††Data missing for 23 patients (RA, n=14; AS, n=9).
‡‡Data missing for 10 patients (RA, n=3; PsA, n=1; AS, n=6) and not evaluable for 45 patients (1.3%; RA, n=21 (1.1%); PsA, n=16 (2.5%); AS, n=8 
(1.0%)).
§§Includes sulfasalazine and mesalazine.
¶¶Includes gold compounds, azathioprine/6-mercaptopurine, cyclosporine and tacrolimus.
***Data missing for 75 patients (RA, n=42; PsA, n=16; AS, n=17).
†††Data missing for 35 patients (RA, n=22; PsA, n=8; AS, n=4).
AS, ankylosing spondylitis; BIPQ, Brief Illness Perception Questionnaire; GC, glucocorticoid; IMID, immune-mediated inflammatory disease;  
MMAS-4©, 4-item Morisky Medication Adherence Scale; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; 
RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.
Table 1 Continued
of patients with RA, PsA and AS, respectively; a ‘partial’ 
response was reported in 48.5%, 42.6% and 38.2% of 
patients with RA, PsA and AS; and a ‘no’ response was 
reported in 2.9%, 2.1% and 3.1% of patients with RA, 
PsA and AS.
treatment characteristics
Patients with RA had a significantly longer mean dura-
tion of current treatment (5.3 years) compared with 
patients with PsA and AS (4.1 and 3.8 years, respec-
tively). Among patients with RA, the largest proportion 
(58.1%) received csDMARD therapy (±GC), whereas in 
patients with AS, the largest proportion were receiving 
TNFi monotherapy (46.1%). In patients with PsA, 
approximately one-third were receiving csDMARD 
therapy, one-third TNFi monotherapy and one-third 
csDMARD-TNFi combination therapy (table 1). The 
most frequently used current systemic compounds were 
methotrexate (±other therapies) in patients with RA 
(72.0%) and TNFis (±other therapies) in patients with 
PsA (65.5%) and AS (79.8%).
BiPQ and BMQ-specific findings
Of BIPQ items used in subsequent analyses, only Time-
line (ie, perception of continuing length of illness) 
differed significantly (highest in PsA, lowest in AS) 
among the three rheumatic disease groups. Patients 
with AS had a significantly lower BMQ-Specific Necessity 
score compared with patients with RA and PsA; patients 
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with RA had a significantly higher mean BMQ-Specific 
Concerns score compared with patients with PsA and AS.
Medication adherence and attitudes
High adherence (MMAS-4© score=4) to a given treat-
ment was similar among patients with RA (OR, 1.106; 
95% CI 0.763 to 1.605 and PsA (reference group; OR=1) 
but significantly lower in patients with AS (OR, 0.424; 
95% CI 0.263 to 0.685). The percentage of patients 
with high adherence also appeared to differ between 
treatment regimens (figure 1), although no statistical 
testing was performed because the multivariate regres-
sion analyses allowed adjustment for confounding 
factors. Depending on the treatment, the percentage 
of patients with high adherence was 57.3%–76.3%, 
57.7%–70.4% and 28.2%–70.6% in patients with RA, 
PsA and AS, respectively. Generally, a larger propor-
tion of patients reported high adherence to TNFis with 
or without concomitant csDMARDs compared with 
csDMARDs and NSAIDs (AS). BMQ attitudinal segmen-
tation revealed that large proportions of patients in 
every rheumatic IMID group were accepting (high 
treatment necessity beliefs/low concerns; 44.3%–49.4% 
of patients) towards their medications (online supple-
mentary figure 1). However, 41.9%–47.3% of patients 
were ambivalent (high treatment necessity beliefs/high 
concerns) towards their medications. Few patients were 
indifferent (low necessity beliefs/low concerns) or 
sceptical (low necessity beliefs/high concerns).
Factors affecting medication adherence
current treatment type
The full starting models for multivariable regression 
analyses of treatment adherence, before backwards 
elimination of factors, are shown in online supple-
mentary figure 2. In multivariable regression analysis, 
several types of treatment had a positive association 
with treatment adherence in RA and AS, although not 
in PsA (table 2). TNFis with or without csDMARDs 
had the most significantly greater ORs for adherence 
compared with csDMARD monotherapy in patients 
with RA (range, 3.63–5.45) and compared with NSAID 
monotherapy in patients with AS (range, 6.33–22.69). 
csDMARDs within csDMARD-TNFi combination 
therapy were significantly associated with greater 
adherence compared with csDMARD monotherapy 
in patients with RA (OR, 2.09). NSAIDs as part of any 
combination therapy in patients with AS were not asso-
ciated with significantly greater adherence compared 
with NSAID monotherapy.
Other factors
In multivariable regression analysis, older age (all three 
IMIDs) and white race (RA and AS) were significantly asso-
ciated with better treatment adherence, but sex was not 
significantly associated with adherence in any of the three 
rheumatic IMIDs (table 2). Illness perception (higher 
BIPQ Emotional Representation scores, indicating greater 
emotional impact) was significantly associated with worse 
treatment adherence in patients with AS only. None of 
the disease-related and medication-related factors, such as 
disease activity or disease duration, were consistently associ-
ated with medication adherence across the three rheumatic 
diseases. Having >3 pretreatments was significantly asso-
ciated with worse medication adherence only in patients 
with AS. In patients with PsA, longer duration of current 
treatment was significantly associated with worse medica-
tion adherence, whereas complete treatment response 
was significantly associated with better adherence. Across 
all three indications, higher BMQ-Specific Necessity beliefs 
were associated with higher treatment adherence, whereas 
higher BMQ-Specific Concerns in patients with RA and 
higher BMQ-General Harm beliefs in patients with RA and 
PsA were significantly associated with poorer adherence.
Because race was highly dependent on geographic 
region, further analyses explored adherence models in 
which both race and geographic region were included as 
factors. In these models, geographic region was treated 
as a fixed variable because geographic categorisation 
was part of the study design. The full starting models 
for multivariable regression analyses of treatment adher-
ence, before backwards elimination of factors, are shown 
in online supplementary figure 3. In multivariable regres-
sion analysis (online supplementary table 1), the pattern 
and magnitude of factors in relation to adherence were 
mostly similar to the findings from the models without 
geographic region (table 2). However, in the multivari-
able model with geographic factors, race was no longer 
significant and was automatically removed from the 
model (online supplementary table 1).
Predictive adherence models
Full models (up to 10 variables)
Three variables were shared across the full adherence 
prediction models for RA, PsA and AS: type of treat-
ment, age and medication beliefs (BMQ-Specific Neces-
sity score). In patients with RA, the best full adherence 
prediction model (AUROC, 0.68) included five varia-
bles besides the common ones: race, medication beliefs 
(BMQ-Specific Concerns and BMQ-General Harm scores), 
illness perception (score for BIPQ item 2 (Timeline) 
with regard to continuing length of illness) and disease 
duration (online supplementary table 2). In patients with 
PsA, the best full model (AUROC, 0.68) included three 
variables besides the common ones: medication beliefs 
(BMQ-General Harm score), duration of current treat-
ment and complete treatment response. In patients with 
AS, the best full model (AUROC, 0.74) included three 
variables besides the common ones: race, illness percep-
tion (score for BIPQ item 7 (Coherence) regarding 
understanding of the disease), and number of prior 
treatments.
Simplified models (four variables)
Two variables were included in each simplified adherence 
prediction model for RA, PsA and AS: type of treatment 
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Figure 1 Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Adherence 
was defined as a binary variable with levels ‘highly adherent’ (MMAS-4©=4) and ‘not highly adherent’ (MMAS-4©<4). 
Treatments: csDMARD mono=csDMARDs±GCs; csDMARD-NSAID combination=csDMARDs+NSAIDs±GCs; NSAID 
mono=NSAIDs±GCs; TNFi mono=TNFi±GCs; TNFi-csDMARD combination=TNFi+csDMARDs±NSAIDs±GCs; TNFi-
NSAID combination=TNFi+NSAIDs±GCs. AS, ankylosing spondylitis; csDMARD, conventional synthetic disease-modifying 
antirheumatic drug; GC, glucocorticoid; IMID, immune-mediated inflammatory disease; MMAS-4©, 4-item Morisky Medication 
Adherence Scale; mono, monotherapy; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid 
arthritis; TNFi, tumour necrosis factor inhibitor.
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Table 2 Multivariable logistic regression analysis of treatments and other factors associated with medication adherence*
Parameter (retained based on 
backward selection)
Component 
being rated
OR (95% CI)†
RA population PsA population AS population
Treatment
  csDMARD-TNFi combination TNFi 5.45 (3.35 to 8.87)‡ 1.22 (0.54 to 2.75) 22.69 (6.34 to 81.21)‡
  NSAID-TNFi combination TNFi NA NA 6.33 (1.84 to 21.84)‡
  TNFi monotherapy TNFi 3.63 (1.72 to 7.69)‡ 1.23 (0.55 to 2.73) 13.10 (4.27 to 40.18)‡
  csDMARD monotherapy csDMARD Reference Reference 1.27 (0.20 to 7.86)
  csDMARD-TNFi combination csDMARD 2.09 (1.35 to 3.25)‡ 0.50 (0.22 to 1.10) 3.23 (0.99 to 10.58)
  NSAID-csDMARD combination csDMARD NA NA 1.19 (0.28 to 5.08)
  csDMARD-TNFi combination NSAID NA NA 1.69 (0.38 to 7.57)
  NSAID-TNFi combination NSAID NA NA 1.15 (0.33 to 4.04)
  NSAID-csDMARD combination NSAID NA NA 1.19 (0.28 to 5.08)
Sociodemographic factors
  Age, years 1.05 (1.03 to 1.06)‡ 1.07 (1.04 to 1.11)‡ 1.03 (1.01 to 1.06)‡
  Race (white vs other) 2.25 (1.51 to 3.36)‡ ― 3.10 (1.66 to 5.78)‡
  Sex (female vs male) ― ― 1.73 (0.96 to 3.12)
Illness perception
  BIPQ item 1—Consequences ― ― 1.10 (0.99 to 1.23)
  BIPQ item 2—Timeline 1.08 (1.00 to 1.17) ― ―
  BIPQ item 8–Emotional 
Representation
― ― 0.86 (0.77 to 0.95)‡
Disease-/medication-related factors
  Disease duration, years 0.97 (0.95 to 0.99)‡ ― ―
  Number of pretreatments (>3 vs 
≤3)
― ― 0.34 (0.16 to 0.72)‡
  Duration of current treatment, 
years
― 0.91 (0.85 to 0.97)‡ ―
  Treatment response (complete vs 
non-complete)§
― 2.19 (1.17 to 4.09)‡ ―
Beliefs factors
  BMQ-Specific Necessity 1.12 (1.07 to 1.18)‡ 1.13 (1.04 to 1.23)‡ 1.18 (1.09 to 1.28)‡
  BMQ-Specific Concerns 0.92 (0.87 to 0.97)‡ ― ―
  BMQ-General Harm 0.88 (0.83 to 0.95)‡ 0.85 (0.77 to 0.94)‡ ―
― = eliminated from model; NA=not applicable (NSAIDs were only taken by patients with AS; therefore there are no data for NSAID-containing 
regimens for patients with RA and PsA).
*Adherence was defined as a binary variable: highly adherent (MMAS-4© score=4) or not highly adherent (MMAS-4© score <4).
†Except where noted, ORs represent the impact of treatment vs reference (csDMARD in csDMARD monotherapy for RA and PsA; NSAID 
monotherapy for AS) or the impact of a 1-unit or 1 year increase (other factors); empty cells denote that a variable was not selected in the regression 
model for the respective indication.
‡P<0.05 vs OR of 1.
§Determined by treating physician; treatment response was categorised as ‘complete response’, ‘partial response’, ‘no response’ or ‘not evaluable’.
AS, ankylosing spondylitis; BIPQ, Brief Illness Perception Questionnaire; BMQ, Beliefs about Medicines Questionnaire; GC, glucocorticoid; IMID, 
immune-mediated inflammatory disease; MMAS-4©, 4-item Morisky Medication Adherence Scale; NA, not applicable; NSAID, non-steroidal anti-
inflammatory drug; OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional 
synthetic disease-modifying antirheumatic drug.
and age. In patients with RA, the best simplified adher-
ence prediction model (AUROC, 0.64) included two 
variables besides the common ones: race and medication 
beliefs (BMQ-General Harm score (online supplemen-
tary table 2). In patients with PsA, the best simplified 
model (AUROC, 0.64) included two variables besides 
the common ones: medication beliefs (BMQ-General 
Harm score) and duration of disease. In patients with AS, 
the best simplified model (AUROC, 0.72) included two 
variables besides the common ones: race and medication 
beliefs (BMQ-Specific Concerns score).
Predicted probabilities of high adherence in the simpli-
fied models ranged widely (RA, 28.6%–96.2% (table 3); 
PsA, 21.7%–95.5% (table 4); AS, 5.0%–94.1% (table 5)). 
According to the simplified models, the highest predicted 
probability of high adherence was to TNFi treatment 
(especially in combination with csDMARDs; tables 3–5). 
In patients with RA and PsA, higher adherence was 
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Table 3 Predicted probability of high adherence to maintenance treatments per posthoc simplified rheumatoid arthritis model
Treatment†‡
Component 
being rated
Predicted high adherence* probability (% (95% CI)) in patients with RA (n=1943)
White patients Non-white patients
Low BMQ-General 
Harm Score (<11)
High BMQ-General 
Harm Score (≥11)
Low BMQ-General 
Harm Score (<11)
High BMQ-General 
Harm Score (≥11)
Age ≥58 years
  csDMARD-TNFi combination TNFi 96.2 (93.8 to 97.7) 92.3 (87.9 to 95.2) 91.0 (85.5 to 94.5) 82.6 (74.0 to 88.8)
  TNFi monotherapy TNFi 94.5 (89.6 to 97.2) 89.0 (80.5 to 94.1) 87.2 (77.0 to 93.3) 76.3 (61.5 to 86.6)
  csDMARD-TNFi combination csDMARD 90.8 (86.4 to 93.9) 82.3 (75.1 to 87.7) 79.6 (70.8 to 86.2) 64.7 (53.5 to 74.6)
  csDMARD monotherapy csDMARD 84.9 (79.6 to 89.0) 72.6 (65.0 to 79.0) 69.0 (59.6 to 77.0) 51.1 (41.2 to 61.0)
Age <58 years
  csDMARD-TNFi combination TNFi 90.7 (86.1 to 93.9) 82.1 (74.6 to 87.8) 79.4 (71.0 to 85.8) 64.5 (53.8 to 74.0)
  TNFi monotherapy TNFi 86.8 (77.6 to 92.6) 75.7 (62.1 to 85.5) 72.3 (57.6 to 83.4) 55.2 (39.0 to 70.3)
  csDMARD-TNFi combination csDMARD 79.0 (71.9 to 84.7) 64.0 (54.2 to 72.7) 59.8 (49.7 to 69.2) 41.3 (31.3 to 51.9)
  csDMARD monotherapy csDMARD 68.2 (60.8 to 74.8) 50.3 (41.7 to 58.9) 45.9 (37.3 to 54.9) 28.6 (21.5 to 36.9)
*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the American College of Rheumatology and European League Against Rheumatism.39 40
BMQ, Beliefs about Medicines Questionnaire; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic 
disease-modifying antirheumatic drug.
Table 4 Predicted probability of high adherence to maintenance treatments per posthoc simplified psoriatic arthritis model
Treatment†‡
Component 
being rated
Predicted high adherence* probability (% (95% CI)) in patients with PsA (n=635)
Short disease duration (<9 years) Long disease duration (≥9 years)
Low BMQ-General 
Harm Score (<12)
High BMQ-General 
Harm Score (≥12)
Low BMQ-General 
Harm Score (<12)
High BMQ-General 
Harm Score (≥12)
Age ≥51 years
  csDMARD-TNFi combination TNFi 95.1 (88.8 to 98.0) 87.1 (74.7 to 93.9) 90.1 (80.5 to 95.3) 76.0 (59.2 to 87.4)
  TNFi monotherapy TNFi 95.5 (89.4 to 98.2) 88.0 (75.8 to 94.5) 90.9 (81.8 to 95.6) 77.5 (61.3 to 88.2)
  csDMARD-TNFi combination csDMARD 87.9 (77.0 to 94.1) 71.6 (54.3 to 84.3) 77.3 (62.8 to 87.3) 54.2 (36.0 to 71.3)
  csDMARD monotherapy csDMARD 91.7 (83.7 to 96.0) 79.4 (64.4 to 89.1) 83.9 (71.3 to 91.6) 64.3 (45.1 to 79.9)
Age <51 years
  csDMARD-TNFi combination TNFi 82.1 (69.2 to 90.3) 61.4 (43.0 to 77.0) 68.3 (51.3 to 81.4) 42.7 (24.9 to 62.6)
  TNFi monotherapy TNFi 83.3 (71.4 to 90.9) 63.3 (45.7 to 78.0) 70.0 (54.8 to 81.8) 44.7 (27.6 to 63.2)
  csDMARD-TNFi combination csDMARD 63.1 (47.2 to 76.6) 37.2 (22.0 to 55.5) 44.5 (28.5 to 61.7) 21.7 (10.7 to 39.3)
  csDMARD monotherapy csDMARD 72.3 (57.8 to 83.2) 47.5 (30.0 to 65.6) 55.0 (37.0 to 71.9) 29.8 (14.9 to 50.6)
*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the European League Against Rheumatism.41
BMQ, Beliefs about Medicines Questionnaire; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic 
disease-modifying antirheumatic drug.
seen in older patients with low treatment harm beliefs; 
in patients with AS, higher adherence was seen in older 
patients with low treatment concerns. In patients with 
RA and AS, the predicted probability of high adherence 
was greater in white patients compared with non-white 
patients who otherwise had the same characteristics; 
in patients with PsA, the predicted probability of high 
adherence was greater with duration of disease <9 years 
compared with ≥9 years in patients who otherwise had 
the same characteristics. Thus, for all three IMIDs, clini-
cians may wish to promote adherence in younger patients 
and among those who either had concerns about their 
specific medications or who believed that medications in 
general cause harm, as a higher risk of low adherence was 
found to be related to these factors. Similarly, it also may 
be advisable to emphasise the importance of adherence 
to patients with RA or AS who are not white and patients 
with PsA of long duration.
dIsCussIOn
ALIGN was the first large cross-sectional study to 
explore patients’ beliefs and treatment adherence to 
systemic medication across six IMIDs, including three 
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Table 5 Predicted probability of high adherence to maintenance treatments per posthoc simplified ankylosing spondylitis 
model
Treatment†‡
Component 
being rated
Predicted high adherence* probability (% (95% CI)) in patients with AS (n=812)
White patients Non-white patients
Low BMQ-Specific 
Concerns Score 
(<14)
High BMQ-Specific 
Concerns Score 
(≥14)
Low BMQ-Specific 
Concerns Score 
(<14)
High BMQ-Specific 
Concerns Score 
(≥14)
Age ≥44 years
  csDMARD-TNFi combination TNFi 94.1 (87.6 to 97.3) 90.5 (81.6 to 95.4) 82.2 (66.9 to 91.4) 73.4 (56.3 to 85.5)
  TNFi monotherapy TNFi 90.2 (83.5 to 94.4) 84.6 (75.9 to 90.5) 72.6 (56.7 to 84.3) 61.2 (45.2 to 75.1)
  NSAID-TNFi combination TNFi 82.7 (68.6 to 91.3) 74.0 (57.1 to 85.8) 57.9 (37.2 to 76.1) 45.0 (26.9 to 64.5)
  csDMARD-TNFi combination csDMARD 68.1 (51.5 to 81.1) 56.0 (39.3 to 71.4) 38.1 (21.8 to 57.5) 26.8 (14.8 to 43.6)
  NSAID-csDMARD combination csDMARD 52.8 (28.4 to 76.0) 40.0 (19.6 to 64.5) 24.4 (9.6 to 49.5) 16.1 (6.2 to 35.8)
  csDMARD monotherapy csDMARD 46.7 (17.2 to 78.7) 34.2 (10.7 to 69.3) 20.1 (5.2 to 53.6) 13.0 (3.1 to 41.1)
  NSAID-TNFi combination NSAID 44.5 (26.5 to 64.0) 32.3 (17.7 to 51.5) 18.7 (8.4 to 36.7) 12.1 (5.3 to 25.3)
  NSAID-csDMARD combination NSAID 45.8 (22.8 to 70.8) 33.5 (15.2 to 58.5) 19.6 (7.3 to 43.1) 12.7 (4.6 to 30.3)
  NSAID monotherapy NSAID 48.7 (27.6 to 70.2) 36.1 (18.6 to 58.2) 21.4 (8.9 to 43.3) 14.0 (5.6 to 30.8)
Age <44 years
  csDMARD-TNFi combination TNFi 86.0 (73.6 to 93.1) 78.5 (63.1 to 88.7) 63.9 (45.2 to 79.1) 51.3 (34.1 to 68.1)
  TNFi monotherapy TNFi 77.9 (67.3 to 85.7) 67.7 (55.4 to 77.9) 50.3 (35.5 to 65.0) 37.6 (25.4 to 51.6)
  NSAID-TNFi combination TNFi 64.6 (46.6 to 79.2) 52.1 (34.3 to 69.4) 34.4 (19.7 to 53.0) 23.8 (13.0 to 39.6)
  csDMARD-TNFi combination csDMARD 44.9 (28.2 to 62.9) 32.7 (19.0 to 50.2) 19.0 (9.7 to 33.9) 12.3 (6.1 to 23.0)
  NSAID-csDMARD combination csDMARD 29.9 (12.7 to 55.6) 20.3 (8.1 to 42.3) 11.0 (3.8 to 27.4) 6.8 (2.4 to 17.9)
  csDMARD monotherapy csDMARD 25.1 (7.2 to 59.2) 16.6 (4.2 to 47.3) 8.8 (2.0 to 30.8) 5.4 (1.2 to 21.4)
  NSAID-TNFi combination NSAID 23.4 (12.0 to 40.8) 15.4 (7.3 to 29.6) 8.1 (3.4 to 17.9) 5.0 (2.1 to 11.5)
  NSAID-csDMARD combination NSAID 24.4 (9.8 to 49.1) 16.1 (6.1 to 36.4) 8.5 (2.9 to 22.7) 5.2 (1.8 to 14.6)
  NSAID monotherapy NSAID 26.6 (12.6 to 47.7) 17.7 (7.8 to 35.5) 9.4 (3.6 to 22.3) 5.8 (2.2 to 14.5)
*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the American College of Rheumatology, Assessment of Spondyloarthritis International 
Society and the European League Against Rheumatism.22–24
AS, ankylosing spondylitis; BMQ, Beliefs about Medicines Questionnaire; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor 
inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.
rheumatological diseases. In all three evaluated rheu-
matic diseases (RA, PsA and AS), higher treatment 
necessity beliefs were more consistently associated with 
medication adherence than disease-related or medi-
cation-related factors. The direct positive relationship 
of TNFi treatment with necessity beliefs in ALIGN16 
appeared to be associated with higher medication 
adherence in patients with RA and AS, although not 
in patients with PsA. Models that used subsets of the 
key factors had moderate ability to predict medication 
adherence in patients with RA, PsA and AS. The adher-
ence prediction models were developed via two distinct 
approaches. The first approach used automated selec-
tion of variables to determine which of a large number of 
potential factors produced models with a higher predic-
tive performance. The second approach used a prog-
nostic model with only one categorical predictor (treat-
ment type) and three other dichotomized predictors; 
although the simpler models had slightly less predictive 
power than the models from the first approach, they 
would be easier to integrate into clinical practice. In 
applied psychology and prediction of future behav-
iour, AUROC values approximately >0.70 are consid-
ered strong effects.26 The predictive accuracy of our AS 
adherence prediction model exceeded an AUROC of 
0.70 and appeared to be of higher accuracy compared 
with those of the RA and PsA models.
To our knowledge, our models are the first that have 
been developed to estimate the probability of high 
adherence to systemic therapies in patients with RA, 
PsA and AS. Thus, no other adherence models are 
available for comparison to determine the value of our 
models. Adherence prediction models in other diseases 
showed higher predictive accuracy.27–32 However, our 
adherence prediction models cannot be compared 
with those models because of differences in the aims of 
the previously published models, their analysed patient 
populations and diseases, the definitions and measure-
ment of adherence and compliance and study design 
(eg, longitudinal vs cross-sectional design; single-vari-
able model vs multivariable model). The moderate 
predictive accuracy of our models may be the result of 
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unidentified factors that could affect adherence on an 
individual level but which are not identifiable in a large 
patient population. The degree of self-reported high 
medication adherence varied widely among patients 
with RA, PsA and AS in ALIGN, consistent with a system-
atic review of findings from other studies.6 The reason 
for a higher observed adherence to TNFi’s compared 
with other treatments in ALIGN cannot be explained 
by the results of this study but could stem from a favour-
able balance between perceptions of treatment neces-
sity versus concerns about adverse effects, which would 
be in line with multiple reports that found a role for 
such beliefs in affecting adherence.8 33–37 Because many, 
and in some countries all, patients receiving TNFi’s or 
other biological or targeted synthetic DMARDs are 
enrolled in a registry (particularly in Europe), their 
physicians or other healthcare providers will regu-
larly monitor their disease in a structured manner; 
this could also have a positive effect on adherence. In 
addition to beliefs about treatments, factors that were 
significantly associated with high medication adher-
ence in ALIGN notably included greater age and white 
race (the latter interrelated with geographic region). 
Interestingly, disease-related factors were infrequently 
associated with high adherence when the variables were 
considered across the three different IMID groups. The 
limited number of significant strong predictors did, 
however, facilitate development of adherence predic-
tion models with manageable numbers of components. 
Each of the three final models shared type of treatment 
and age as factors; however, not all treatments were 
comparable among IMIDs, because NSAIDs (which are 
considered disease modifying and cornerstone first-line 
treatment in AS but not RA or PsA) were modelled only 
for the AS population. Heterogeneity in the structures 
of the three final models, perhaps deriving ultimately 
from the dissimilar experiences of patients with RA, 
PsA and AS, underscores the need for separate analysis 
in each IMID to enable accurate prediction of medica-
tion adherence. Although in the present study separate 
analyses were needed for the three conditions investi-
gated because of different profiles, it would be desir-
able to have a single adherence prediction model for 
all three diseases; based on the present study, it may be 
possible to develop such a tool in the future.
Several limitations of ALIGN and the current analyses 
should be noted. First, and perhaps most important, 
the number of patients with RA was greater than the 
numbers of patients with PsA and AS; consequently, 
statistical power was dissimilar in the three groups. This 
could have impaired detection of significant effects in 
some analysis groups. Second, as expected from the 
epidemiology of each condition, patients in the three 
different rheumatic IMID populations differed in their 
sociodemographic, disease and treatment characteris-
tics. For example, a higher percentage of patients with 
AS received TNFi compared with patients with RA and 
PsA; this presumably was due to the general inefficacy 
of csDMARDs and other biologics for treating AS.24 
Therefore, it was impossible to pool data across rheu-
matic diseases or to produce an adherence prediction 
model that would be applicable to all three conditions. 
Third, the proportion of white patients within each 
IMID group depended strongly on the geographic 
region, and adherence as well as treatment patterns 
may have been linked to country-specific factors, 
such as restricted access to certain medications, and 
cultural beliefs. The interdependence of race and 
geographic region was confirmed by using models in 
which geographic region was a fixed factor, resulting 
in the automatic elimination of race as an independent 
predictive factor. Fourth, disease activity was judged 
subjectively by the investigators, rather than assessed 
by some objective measure. Fifth, treatment adher-
ence was based on patient self-reporting and was not 
confirmed by objective measures. However, patients 
completed and turned in the questionnaires in private 
and anonymously so that they could answer honestly 
without worries about censure. Nevertheless, some 
other means to measure medication acquisition may 
be helpful and, indeed, consistent with the results of 
the present study. A recent study assessed adherence 
to medications in patients with RA (n=178) using an 
objective measure of adherence (medication posses-
sion ratio) and found that 89% of patients showed good 
adherence to biological DMARDs.38 Sixth, by design, 
the survey captured data from only a single point in 
time; however, information was also collected on the 
patients’ disease history. Finally, development of the 
final adherence prediction models via AUROC anal-
ysis was a posthoc effort, although the identification of 
individual predictive factors by multivariable regression 
analysis was prospectively planned.
In conclusion, patients with rheumatic IMIDs who 
participated in a large, multicountry patient survey 
study exhibited treatment beliefs that were strongly 
associated with adherence to systemic medications. 
Among the treatment regimens that were examined, 
adherence was highest for TNFis, whether as mono-
therapy or in combination with other agents. Simpli-
fied models that combined treatment beliefs with other 
key significant predictive factors, such as age, race and 
treatment duration, provided moderate power in esti-
mating adherence to different systemic medications. 
These models may be useful in tailoring interventions 
to increase adherence in individual patients, as the 
demographic predictors can indicate whom to target, 
whereas the medication belief predictors indicate what 
to target in an adherence support intervention. Tools 
to facilitate use of these models in community rheu-
matology practice would allow application and further 
validation in real-world populations. Because ALIGN 
was the first large, cross-sectional study of its kind, 
confirmatory research using more objective criteria is 
needed.
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